Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY1R | P25929 | 3/20 | 0.66 |
| ▸ | NPY2R | P49146 | 3/20 | 0.66 |
| ▸ | NPY4R | P50391 | 3/20 | 0.66 |
| ▸ | GHSR | Q92847 | 7/20 | 0.64 |
| ▸ | ERAP2 | Q6P179 | 3/20 | 0.58 |
| ▸ | IL1RN | P18510 | 1/20 | 0.58 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.57 |
| ▸ | ERAP1 | Q9NZ08 | 2/20 | 0.57 |
| ▸ | LNPEP | Q9UIQ6 | 2/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29578675 | 1.00 | NPY1R (0.66) | NPY1RNPY2RNPY4RGHSRERAP2 | |
| SCHEMBL29508663 | 0.97 | NPY1R (0.65) | NPY1RNPY2RNPY4RGHSRERAP2 | |
| SCHEMBL30179569 | 0.97 | GHSR (0.64) | NPY1RNPY2RNPY4RGHSRERAP2 | |
| SCHEMBL29896929 | 0.96 | GHSR (0.63) | NPY1RNPY2RNPY4RGHSRERAP2 | |
| SCHEMBL29508662 | 0.96 | GHSR (0.63) | NPY1RNPY2RNPY4RGHSRERAP2 | |
| SCHEMBL31731732 | 0.95 | GHSR (0.62) | NPY1RNPY2RNPY4RGHSRERAP2 | |
| SCHEMBL29577418 | 0.95 | GHSR (0.68) | NPY1RNPY2RNPY4RGHSR | |
| SCHEMBL29577125 | 0.95 | GHSR (0.68) | NPY1RNPY2RNPY4RGHSR | |
| SCHEMBL31236189 | 0.94 | GHSR (0.62) | NPY1RNPY2RNPY4RGHSRERAP2 | |
| SCHEMBL29508714 | 0.94 | GHSR (0.64) | NPY1RNPY2RNPY4RGHSRERAP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250161505-A1 | CD206 Targeted Peptide Conjugates and Methods of Using the Same | THE UAB RESEARCH FOUNDATION | 2025-05-22 | — | — | US | disclosed |
| WO-2023154564-A9 | CD206 TARGETED PEPTIDE CONJUGATES AND METHODS OF USING THE SAME | Riptide Bioscience, Inc. (US) | 2023-12-07 | — | — | WO | disclosed |
| WO-2023154564-A2 | CD206 TARGETED PEPTIDE CONJUGATES AND METHODS OF USING THE SAME | Riptide Bioscience, Inc. (US) | 2023-08-17 | — | — | WO | disclosed |
| EP-3206704-B1 | PEPTIDES HAVING ANTI-INFLAMMATORY PROPERTIES | RIPTIDE BIOSCIENCE INC (US) | 2022-04-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250161505-A1 | CD206 Targeted Peptide Conjugates and Methods of Using the Same | CD209, SIGLEC7, SIGLEC9 | NPY1R 1039/4885NPY2R 1067/4885NPY4R 727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.